Nestle, GE diagnostics
This article was originally published in The Tan Sheet
Executive SummaryGeneral Electric's centralized R&D organization and the Nestle Research Center will collaborate to better understand the relationships between physical make-up, metabolism, lifestyle and nutrition, the firms announce May 14. The partnership brings together Switzerland-based Nestle's expertise in health and nutrition with London-based GE's diagnostics work, the companies say. Nestle scientists will use GE's Lunar iDXA imaging technology system to measure body fat, muscle and bone mineral density and study correlations between lifestyle habits, body composition and metabolic data to better comprehend biological health drivers, the firms say. The firms aim for the results to direct development of non-invasive, quick and accurate clinical assessment tools to evaluate nutritional impact on metabolism...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.